Varian Medical Systems Investor Presentation — January 2018

Document content

New revenue accounting

standard (ASC 606) and

Gary E. Bischoping Jr., Chief Financial Officer

Magnus Momsen, Chief Accounting Officer

J. Michael Bruff, Vice President Investor RelationsFORWARD -LOOKING STATEMENTS

Except forhistorical information, this presentation contains forward -looking statements within themeaning ofthePrivate Securities Litigation Reform Actof1995 .Statements concerning industry outlook, including

growth drivers, future trends incancer incidence and trends incancer treatment needs, demand, innovation and growth opportunities ;Varian Medical System, Inc.’s(”Varian” orthe “company”) future orders,

revenues, backlog orearnings growth ;future financial results ;market acceptance ofortransition tonew products ortechnology such asour EdgeTMradiosurgery system, TrueBeam®,HyperArcTM,360 OncologyTM,

HALCYONTM,image -guided radiation therapy, stereotactic radiosurgery and proton therapy, and any statements using the terms “could”, “believe”, “expect”, “outlook”, “anticipate”, ”vision”, “estimate”, “future”,

“horizon”, “aiming”, “driving”, “target” orsimilar statements areforward -looking statements that involve risks and uncertainties that could cause thecompany’s actual results todiffer materially from those anticipated .

Such risks and uncertainties include global economic conditions and changes totrends forcancer treatment regionally ;theimpact ofchanges totheAffordable Health Care forAmerica Act(including excise taxes on

medical devices) and any further healthcare reforms (including changes toMedicare and Medicaid), and/or changes tothird -party reimbursement levels ;currency exchange rates and taxrates ;demand forthe

company’s products ;thecompany’s ability todevelop, commercialize, and deploy new products ;thecompany’s ability tomeet Food and Drug Administration (FDA) and other regulatory requirements forproduct

clearances ortocomply with FDA and other regulatory regulations orprocedures, changes inthe regulatory environment, including with respect toFDA requirements ;the company’s assessment ofthe goodwill

associated with itsparticle therapy business, challenges associated with thesuccessful commercialization ofthecompany’s particle therapy business ;therisks associated with providing financing fortheconstruction and

start -upoperations ofproton therapy centers ;theeffect ofadverse publicity ;thecompany’s reliance onsole orlimited -source suppliers ;thecompany’s ability tomaintain orincrease margins ;theimpact ofcompetitive

products and pricing ;thepotential loss ofkeydistributors orkeypersonnel ;challenges topublic tender awards and theloss ofsuch awards orother orders ;theimpact ofthenew TaxCuts and Jobs Act;and theother